| Name | Title | Contact Details |
|---|
RainDance Technologies, Inc. provides microdroplet-based solutions for single molecule and single cell analysis in the life sciences industry. The company’s RainStorm technology generates various discrete droplets that can encapsulate a single molecule, single cell, or reaction. It offers RDT 1000, a solution that amplifies genomic loci and leverages the sensitivity and specificity of polymerase chain reaction methodology; and ThunderStorm System, a fully automated high-throughput targeted sequencing solution that enables researchers to determine all variation contained in any region of the genome. The company also provides research screening panels, including ASDSeq for autism spectrum disorder research; XSeq for human X-chromosome research; and HLASeq for human leukocyte antigen and major histocompatibility complex research. In addition, it offers sequence enrichment consumables kits that comprise reagents and consumables, and custom-order libraries; and RainDrop Digital PCR System that transforms the performance of molecular assays by enabling digital answers across various applications, including tumor allele detection, gene expression, copy number variation, and SNP measurement. Further, the company provides remote and onsite response for various emergency repairs, including labor and travel, replacement parts and consumables, software revisions, and preventative maintenance. Its RainStorm technology serves various biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection. The company was founded in 2004 and is headquartered in Lexington, Massachusetts.
PMG of Santa Cruz is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Santa Cruz, CA. To find more information about PMG of Santa Cruz, please visit www.pmgscc.com
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.
We’re a global company that designs and manufactures really great hearing instruments. That’s what we do. More important is why we do it. We do it because hearing matters. We partner with dedicated hearing healthcare professionals around the world who share our belief that hearing well is a beautiful thing.
Nussentials is a Eufaula, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.